| 1.08 -0.02 (-1.82%) | 10-12 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.26 | 1-year : | 2.92 |
| Resists | First : | 1.94 | Second : | 2.5 |
| Pivot price | 1.5  |
|||
| Supports | First : | 1.03 | Second : | 0.86 |
| MAs | MA(5) : | 1.14 |
MA(20) : | 1.63 |
| MA(100) : | 3.37 |
MA(250) : | 11.72 |
|
| MACD | MACD : | -0.4 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 6.1 |
D(3) : | 7.7 |
| RSI | RSI(14): 15.2 |
|||
| 52-week | High : | 26.96 | Low : | 1.03 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ICCM ] has closed above bottom band by 11.6%. Bollinger Bands are 58.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 60 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.2 - 1.21 | 1.21 - 1.22 |
| Low: | 1.04 - 1.05 | 1.05 - 1.06 |
| Close: | 1.06 - 1.09 | 1.09 - 1.1 |
Headquartered in Caesarea, Israel, and founded in 2006, IceCure Medical Ltd is a medical device enterprise dedicated to inventing, refining, and marketing innovative solutions for treating human tumors through cryoablation, a freezing process. Their primary offering, the ProSense system, provides a specialized cryoablation therapy specifically for breast tumors.
Tue, 06 Oct 2026
IceCure Expands ProSense® ChoICE Study for Low-Risk Breast Cancer adding Legacy Health in Portland, OR as U.S. Clinical Site - PR Newswire
Mon, 05 Oct 2026
A director will serve until November 2 as IceCure Medical (ICCM) removes his re-election agenda items. - Stock Titan
Mon, 05 Oct 2026
A permanent billing code was not approved for IceCure Medical (ICCM), but facility payments remain. - Stock Titan
Wed, 19 Aug 2026
IceCure Medical Ltd. SEC Filing (Aug 19, 2026) | ICCM EFFECT - Stock Titan
Thu, 13 Aug 2026
IceCure Medical (NasdaqCM:ICCM) Stock Forecast & Analyst Predictions - Simply Wall Street
Tue, 11 Aug 2026
Earnings To Watch: Icecure Medical Ltd (ICCM) Q2 2026 -- GF Value Sees 452% Upside - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 5 (M) |
| Shares Float | 3 (M) |
| Held by Insiders | 51.4 (%) |
| Held by Institutions | 12.6 (%) |
| Shares Short | 52 (K) |
| Shares Short P.Month | 108 (K) |
| EPS | -6.85 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.47 |
| Profit Margin | 0 % |
| Operating Margin | -487.8 % |
| Return on Assets (ttm) | -73.9 % |
| Return on Equity (ttm) | -228.4 % |
| Qtrly Rev. Growth | 72.8 % |
| Gross Profit (p.s.) | 0.3 |
| Sales Per Share | 0.85 |
| EBITDA (p.s.) | -3.55 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -16 (M) |
| Levered Free Cash Flow | -10 (M) |
| PE Ratio | -0.16 |
| PEG Ratio | 0 |
| Price to Book value | 0.31 |
| Price to Sales | 1.26 |
| Price to Cash Flow | -0.32 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|